Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3409 - Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventional study NABUCCO


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Karin Potthoff


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


K. Potthoff1, A. Nusch2, U. Söling3, R. Hansen4, C. Salat5, S. Grebhardt6, J. Harde7, N. Marschner8

Author affiliations

  • 1 Medical Department, iOMEDICO, 79108 - Freiburg/DE
  • 2 Hämatologie Und Internistische Onkologie, Krebszentrum Ratingen, 40878 - Ratingen/DE
  • 3 Innere Medizin, Hämatologie Und Internistische Onkologie, Innere Medizin, Hämatologie und Internistische Onkologie, 34119 - Kassel/DE
  • 4 Hämatologie Und Onkologie, Onkologische Schwerpunktpraxis Dres. Hansen & Reeb, 67655 - Kaiserslautern/DE
  • 5 Innere Medizin, Hämatologie Und Internistische Onkologie, Hämato-Onkologische Schwerpunktpraxis, 80639 - München/DE
  • 6 Clinical Operations, iOMEDICO, 79108 - Freiburg/DE
  • 7 Statistics, iOMEDICO, 79108 - Freiburg/DE
  • 8 Internal Medicine / Hematology, Praxis für interdisziplinäre Onkologie & Hämatologie, 79110 - Freiburg/DE


Abstract 3409


Nab-paclitaxel (Nab-P) is approved for the treatment of metastatic breast cancer (MBC) after first line therapy and when anthracyclines are not indicated. Clinical trials proved high efficacy and reduced toxicity of nab-P compared to standard taxanes. Real world data of nab-P in MBC, however, are still limited.


The prospective, multicenter, non-interventional NABUCCO study was designed to collect data on effectiveness including overall survival, safety, treatment patterns and quality of life (QoL) in patients (pts) with MBC in real world. QoL was assessed with the validated questionnaires Functional Assessment of Cancer Therapy-General (FACT-G) and the breast cancer and taxane specific modules (FACT-B and FACT-Taxane) at baseline (BL), 3, 6 months. Data were analyzed descriptively. Survival was analyzed with the Kaplan-Meier method.


697 of 705 pts with MBC enrolled at 128 sites in Germany from 4/2012 to 4/2015 were evaluable (median age 62.3 years (yrs) (min-max 29.2-89.3); age ≥65 yrs n = 291 (41.8%), ECOG 0/1 n = 628 (90.1%), prior taxanes n = 419 (60.1%)). 194 pts (27.8%) received 220-260 mg/m2 q3w, 491 pts (70.4%) received weekly nab-P at ≤ 150 mg/m2 (physician’s discretion; 1.7% other). Median overall survival (mOS, months [95% CI]) was 15.6 [14.2-17.2]. No difference was observed with regard to treatment pattern (15.1 [12.3-17.5] q3w vs 16.3 [14.4-18.5] weekly) and age (15.7 [14.0-18.1]


The NABUCCO study confirms survival data from clinical trials in real world without deteriorated global and breast cancer related QoL.

Clinical trial identification


Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.